Alaunos Therapeutics Inc (TCRT) Stock Analysis

$1.605

-0.053 (-3.31%)At close

Loading chart…

High: 1.710
Open: 1.660
VWAP: 1.62
Vol: 35.68K
Mkt Cap: 11.53M
Low: 1.550
Amount: 57.86K
EV/EBITDA, TTM: 0.00

Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.

alaunos.com

AI analysis of Alaunos Therapeutics Inc (TCRT)

sell

Alaunos Therapeutics Inc is not a good buy right now due to its current price of 1.605, a very low RSI of 16.85 indicating oversold conditions, and a significant year-to-date decline of 51.07%. The company is facing ongoing financial losses, with a reported Q2 loss of $952,000, and a forward P/E ratio of 18.48 suggests overvaluation relative to its earnings potential.

Valuation Metrics

The current forward P/E ratio for Alaunos Therapeutics Inc (TCRT) is 18.48, compared to its 5-year average forward P/E of 0.41.

Forward P/E

Strongly Overvalued

5Y Average P/E

0.41

Current P/E

18.48

Overvalued

8.45

Undervalued

-7.63

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

0.02

Current EV/EBITDA

0.00

Overvalued

0.11

Undervalued

-0.07

Forward P/S

Fair

5Y Average P/S

3813.34

Current P/S

0.00

Overvalued

14290.07

Undervalued

-6663.40

Alphio AI Price Scenarios for TCRT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Bull

Bull · 25%TCRT

$3.93

Scenario price

Base

Base · 50%TCRT

$3.76

Scenario price

Bear

Bear · 25%TCRT

$3.71

Scenario price

Events Timeline

2026-05-26 (ET)